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ABSTRACT: The zinc finger protein EVI1 is causally associated
with acute myeloid leukemogenesis, and inhibition of its function
with a small molecule therapeutic may provide effective therapy
for EVI1-expressing leukemias. In this paper we describe the
development of a pyrrole−imidazole polyamide to specifically
block EVI1 binding to DNA. We first identify essential domains
for leukemogenesis through structure−function studies on both
EVI1 and the t(3;21)(q26;q22)-derived RUNX1-MDS1-EVI1
(RME) protein, which revealed that DNA binding to the cognate
motif GACAAGATA via the first of two zinc finger domains
(ZF1, encompassing fingers 1−7) is essential transforming activity. To inhibit DNA binding via ZF1, we synthesized a pyrrole−
imidazole polyamide 1, designed to bind to a subsite within the GACAAGATA motif and thereby block EVI1 binding. DNase I
footprinting and electromobility shift assays revealed a specific and high affinity interaction between polyamide 1 and the
GACAAGATA motif. In an in vivo CAT reporter assay using NIH-3T3-derived cell line with a chromosome-embedded tet-
inducible EVI1-VP16 as well as an EVI1-responsive reporter, polyamide 1 completely blocked EVI1-responsive reporter activity.
Growth of a leukemic cell line bearing overexpressed EVI1 was also inhibited by treatment with polyamide 1, while a control cell
line lacking EVI1 was not. Finally, colony formation by RME was attenuated by polyamide 1 in a serial replating assay. These
studies provide evidence that a cell permeable small molecule may effectively block the activity of a leukemogenic transcription
factor and provide a valuable tool to dissect critical functions of EVI1 in leukemogenesis.
The EVI1 gene was first identified as a site of proviral insertionin retrovirally induced murine myeloid leukemias, which
resulted in activation of the gene with overexpression of at least
three different isoforms, p135, p123, and p103, that possess varying
numbers of C2H2-type zinc fingers. The p135 and p123 isoforms
possess 10 zinc finger motifs in two domains separated by 480
amino acids, suggesting a role in transcriptional regulation. The N-
terminally located zinc finger domain 1 (termed ZF1, and
encompassing fingers 1−7; amino acids 1−249) binds specifically
to GACAAGATA-like sequences;1,2 domain 2 binds GAAGAT-
GAG motif.3 Transformation assays have shown that the N-
terminal, but not the C-terminal, region is required for transforming
activity.4 Transfection assays for transcriptional activation by EVI1
using synthetic reporters bearing EVI1 binding sites indicate that
EVI1 can act as either a transcription repressor5−7 or an
activator.8−10 Indeed, a repression domain that binds the
corepressor CtBP was identified by Palmer et al. and is present
in the p135, p123, and p103 isoforms.7,11,12 The overlap between
the binding motif for domain 1 (GACAAGATA) and the GATA
protein binding site (WGATAR) suggested that EVI1 may bind to
GATA sites in the genome and block the action of differentiation-
promoting GATA proteins.5,6 This possibility was pursued in a
series of in vitro and in vivo studies, from which it was concluded
that high affinity binding by EVI1 to DNA via domain 1 required a
longer sequence than WGATAR,5 specifically GACAAGATA.5
Studies by Delwel et al. indicated that zinc fingers 4−7 within
zinc finger domain 1 (ZF1) of EVI1 are necessary for that domain
to bind to DNA with sequence specificity.2 Through in vitro and in
vivo structure−function studies, we determined that amino acids
Q199 and R205 residing in zinc finger six are critical for sequence-
specific DNA binding. This analysis allowed for the generation of
single amino acid missense mutations (R205N and Q199D) that are
essentially devoid of DNA binding ability.13 Furthermore, through a
series of in vitro and in vivo studies, it was determined that the
nature of EVI1 zinc fingers 1−7 binding to its cognate DNA motif
is high affinity and highly specific.5 To identify in vivo targets for
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EVI1, we devised a tetracycline-regulated EVI1-VP16 chimera that
had the binding specificity of EVI1 zinc finger domain 1 fused to
the potent transcriptional activation domain of VP16. We expressed
this in NIH3T3 fibroblasts under tetracycline regulation and used
gene expression profiling on oligonucleotide microarrays to identify
upregulated genes. This allowed the identification of 16 genes that
were specifically induced by EVI1-VP16 but not by the R205N
mutant that lacked DNA binding.13 The EVI1-VP16-responsive
genes include genes encoding transcription factors (e.g., GATA2),
signaling molecule (e.g., Nik) and extracellular matrix components
(e.g., decorin). For many of these genes, EVI1 binding sites were
identified in cis by a combination of in silico analysis of evolutionary
conserved binding motifs and chromatin immunoprecipitation.
Importantly, most of these sites were occupied by EVI1 both in
fibroblasts and in myeloid leukemia cells overexpressing EVI1.13
These data suggest that these genes were indeed direct targets of
EVI1 in leukemic cells and may contribute to leukemogenesis.
The development of small molecules that block the binding
of EVI1 to DNA may be potential therapeutic strategy for
treatment of acute myeloid leukemia. Hairpin pyrrole−
imidazole (Py-Im) polyamides are a class of synthetic cell
permeable ligands that can be programmed to bind DNA
with high affinity and sequence specificity.14,15 The molecular
recognition properties of these compounds for specific DNA
sequences are encoded by the side-by-side arrangement of
N-methylpyrrole (Py), N-methylimidazole (Im), and N-methyl-3-
hydroxypyrrole (Hp) carboxamides that form distinct hydrogen
bonds to the four Watson−Crick base pairs in the minor groove.
Im/Py pairs distinguish G·C from C·G, whereas Hp/Py specifies
T·A from A·T and Py/Py pairs are degenerate for T·A and A·T.16−18
These small molecules achieve affinities and specificities comparable
to those of DNA binding proteins,19 have been designed to target a
broad repertoire of DNA sequences,20 inhibit the DNA binding of a
wide range of transcription factors, bind to chromatin,21 are cell
permeable,22,23 and have been shown to downregulate endogenous
gene expression in cell culture.24−27
The exact role of DNA binding of EVI1 in leukemogenesis
remains elusive. In this paper, we demonstrate that DNA binding via
ZF1 is essential for malignant transformation. We also describe our
efforts to directly target the EVI1−DNA binding interaction using a
pyrrole−imidazole polyamide. Our results indicate that polyamide 1
significantly blocked the ZF1-mediated interaction between EVI1
and DNA and partially inhibited leukemic cell growth. This study
thus describes a first attempt at inhibiting the leukemogenic activity
of EVI1 with a targeted therapy; this polyamide provides a valuable
tool for dissecting critical ZF1−DNA direct interaction.
■ EXPERIMENTAL PROCEDURES
Polyamide Synthesis. Py-Im polyamides 1−2 were
synthesized on Kaiser oxime resin utilizing solid-phase synthesis
Figure 1. Analysis of zinc finger mutants of EVI1. (A) Ribbon structure of a C2H2 Krüppel-type zinc finger. (B) Amino acid sequence of zinc finger 9
of EVI1, showing the EVI1R769C mutation. Dotted residues are those on the exposed face of the helix and interacting with DNA. (C) Purification of
GST-tagged EVI1. 1. Crude lysates; 2 and 3, glutathione eluant from affinity resin of wildtype protein, fractions 1 and 2; 4 and 5, eluant of EVI1R769C
mutant. (D) Electromobility shift assay using proteins shown in lanes 3 and 5 of panel C, and a 32P-radiolabeled probe containing the
GAAGATGAG motif. Lane 1, probe alone; lanes 2−5, dilutions of wildtype protein as indicated; lanes 6−9, dilutions of mutant protein as indicated.
(E) Upper panel, Western blot analysis of pools of drug-selected retrovirally transduced Rat1cells, infected with the constructs indicated. To the left,
location of molecular weight marker. Band representing hemagglutinin (HA)-tagged EVI1 is indicated at right. The 127 kDa band seen in all lanes
represents background signal. (F) Colonies in soft agar formed after plating transduced Rat1 cells in soft agar. (G) Diagram of the structure of the
RUNX-MDS1-EVI1 (RME) fusion protein product of t(3;21), with mutations R205N and R769C as indicated. Not to scale. (H) Serial replating assay
of transduced primary bone marrow cells from 5-FU-treated C57BL/6 mice. Retrovirally transduced mouse bone marrow cells were plated in
cytokine-supplemented semisolid methylcellulose medium, allowed to form colonies, and then passaged onto secondary and then tertiary plates of
the same medium. The x-axis presents the number of colonies formed on tertiary plating, which represent malignantly transformed cells; each bar
indicates the average of colonies in triplicate plating. Student t test showed the R205N significantly different than vector-transduced control
(p < 0.001). This experiment was repeated with essentially the same results.
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protocols.28 Polyamides were cleaved from resin by aminolysis with
3,3′-diamino-N-methyldipropylamine and HPLC purified, yielding
compounds 5 and 6 (Figure S1). C-terminal isophthalic acid (IPA)
conjugates (polyamides 1 and 2) were synthesized from 5 or 6
utilizing previously reported conditions.26 Detailed experimental
protocols to cleave the benzyl carbamate (Cbz) protecting group
on the chiral β-NH2 turn and transform the resulting amine to the
β-NHAc functionality have been reported elsewhere.29 The benzyl
carbamate (Cbz) protecting group on the chiral β-NH2 turn was
cleaved by our standard conditions.29 Polyamides were purified by
preparative HPLC on an Agilent 1200 Series instrument equipped
with a Phenomenex Gemini preparative column (250 × 21.2 mm,
5 μm) with the mobile phase consisting of a gradient of acetonitrile
(MeCN) in 0.1% CF3CO2H (aqueous). Polyamide purity was
evaluated by analytical HPLC analysis on a Beckman Gold
instrument equipped with a Phenomenex Gemini analytical
column (250 × 4.6 mm, 5 μm), a diode array detector, and the
mobile phase consisting of a gradient of MeCN in 0.1% CF3CO2H
(aqueous). Matrix-assisted, LASER desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) was performed on an
Applied Biosystems Voyager DE-Pro spectrometer using α-cyano-
4-hydroxycinnamic acid as matrix. Electrospray ionization (ESI+)
MS was performed on a Waters Acquity UPLC-LCT Premiere XE
TOF-MS system. Polyamide 1 MALDI-TOF MS calculated for
C65H77N22O12 [M + H]
+ 1357.6, found 1357.2; polyamide 2
MALDI-TOF calculated for C65H77N22O12 [M + H]
+ 1357.6,
found 1357.4.
Thermal melting temperature analysis/UV absorption
spectrophotometry was performed as previously described.29,30
Results from this study are shown in Table 1.
DNase I Footprinting. DNase I footprinting was
performed on a 5′-32P-labeled PCR amplicon essentially as
previously described.31 Primer oligonucleotides (Integrated
DNA Technologies) 5′-AGGCGATTAAGTTGGGTAACG-3′
(forward) and 5′- TCGGCCTCTGCATAAATAAAA-3′ (re-
verse) were designed to amplify a 223 basepair region of p406
surrounding an insert (5′-AGATCTGACAAGATAAATTAA-
GAGATCT-3′) containing the EVI1 binding site (underlined).
The forward primer was radiolabeled using [α-32P]-dATP (MP
Biomedicals) and polynucleotide kinase (Roche). The PCR
product was generated using the primer pair and Expand High
Fidelity PCR Core Kit (Roche) following the manufacturer’s
protocol, and an unradiolabeled PCR amplicon was confirmed
by sequencing (Laragen). The PCR product was purified on a
7% nondenaturing preparatory polyacrylamide gel (5% cross-
link) and visualized by autoradiography. The labeled band was
excised, crushed, and soaked overnight (14 h) in 2 M NaCl.
The gel pieces were removed by centrifugal filtration, and the
DNA was precipitated with 2-propanol (1.5 volumes). The
pellet was washed with 75% ethanol, lyophilized to dryness, and
then resuspended in 1 mL of RNase-free H2O. Footprinting
was performed on 1 μM, 300 nM, 100 nM, 30 nM, 10 nM,
3 nM, 1 nM, 300 pM, 100 pM, 30 pM, and 10 pM solutions of
compounds polyamide 1 (match polyamide) and polyamide 2
(mismatch polyamide), where polyamide solutions were
quantitated using ε = 69 500 M−1 cm−1. All reactions were
carried out in a volume of 400 μL according to the published
procedures.31 Quantitation by storage phosphor autoradiog-
raphy and determination of equilibrium association constants
(Table 2) were as previously described.31 Chemical sequencing
reactions were performed according to published protocols.32,33
Retroviral Constructs. The EVI1R769C mutation was created
with mutagenic oligonucleotides 5′ GTTGCGCACATGA-
CATTGCAGGTTGGAAG 3′ using the dut-ung system34 with
single-stranded p39413 serving as a template. The resultant plasmid,
p684, was confirmed by DNA sequencing and transferred to
pBabe-Puro35 as a BamHI fragment to create p692. To create the
RME fusion, 1.63 kb EcoR1-BglII fragment from a human pBS-
RME plasmid (p495; gift of G. Nucifora) was inserted into EcoR1-
BglII-cut plasmids p394, p620, and p684 to create p798, gs475, and
gs477, respectively. In each of these, the NotI site was replaced
with an EcoR1 site, and the 3.6 kb EcoR1 product was inserted
into pMIGR1 to generate p854, p855, and p856, respectively. The
creation of EVI1R205N mutation has been described previously.
13
Production of Virus. Retroviral stocks were prepared by
calcium phosphate/DNA precipitate-mediated gene transfer
into BOSC cells in the presence of 25 μM chloroquine.
Retroviral plasmid constructs (5 μg per 60 mm plate) were
coprecipitated with pNCA, a plasmid containing a full-length,
functional clone of Mo-MuLV. DNA was allowed to remain on
the cells for 12−18 h, and the medium was then changed. Viral
supernatants were harvested at 48 and 72 h post-transfection.
Viral titers were determined by infecting BAF3 cells and
determining the percent GFP+ at 48 h postinfection.
Transformation Assays. Rat1 fibroblast cells were trans-
duced with pBabe-Puro-based retroviral constructs via retroviral
infection in the presence of 8 μM Polybrene. Cells were
selected in 2 μg/mL puromycin, and population of resistant
cells was assayed by Western blot for protein expression and by
colony formation for malignant transformation. Assays were
performed in triplicate in 0.6% soft agar/DMEM supplemented
with 20% FBS, seeding 1 × 103 cells per 60 mm plate in 3 mL
total volume with a 0.3% agar overlay, also containing DMEM
and 20% FBS. Colonies in the three plates were totalled and
reported in Figure 1. The entire experiment was repeated once.
Table 1. Thermal Stability Data for Polyamides 1 and 2 Complexes with DNAa
aAll values reported are derived from at least three melting temperature experiments with standard deviations indicated in parentheses. ΔTm values
are given as Tm
(DNA/polyamide) − Tm(DNA). The propagated error in Tm measurements is the square root of the sum of the square of the standard
deviations for the Tm values.
Table 2. Equilibrium Association Constants (M−1)
Determined for Polyamides 1 and 2
1 2
site I:
TGACAA
1.7 (±0.3) × 1010 1.0 (±0.3) × 108
site II:
TGTAAA
3.1 (±0.6) × 109 5.5 (±1.0) × 108
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RME mutants were assayed by serial replating:36 Bone marrow
was harvested from male Balb/c mice 5d following injection
with 5-fluorouracil. Cells were flushed from the marrow with
Tissue Dissociation Medium (Life Sciences) at room temper-
ature. Mononuclear cells were purified on a metrizamide
cushion (Histopaque, Sigma-Aldrich), washed in phosphate
buffered saline, and then cultured in bone marrow culture
medium (DMEM/10% FBS/pen/strep/amphotericinB/6 ng/mL
IL-3, 10 ng/mL IL-6, and 100 ng/mL SCF). On the day
following bone marrow harvest, cells were infected with
retrovirus by “spinfection” as described.37 The serial replating
assay was performed as described.36
Electromobility Shift Assay. ZF2 of EVI1 from N710 to
E821
38 was inserted as a PCR product into the EcoR1 site of
plasmid pGEX1N; the PCR product was generated with primers
5′ GATGAATTCAACACCCTGCCAGAG 3′ and 5′ GAC-
GAATTCTAGCTCTGAGTGAGG 3′. This construct was used
to produce GST-tagged protein which was purified as described.39
Hexahistidine-tagged amino-terminal fragment of EVI1 (amino
acids 1−249, encompassing ZF1) was purified from IPTG-
induced E. coli Rosetta strain harboring a pET-22b+-EVI1 plasmid
by nickel affinity chromatography as described.13 The elute was
dialyzed against 12.5% glycerol, 5 mM MgCl2, 0.01 mM ZnSO4,
50 mM NaCl, 10 mM DTT, 50 mM HEPES, pH 7.9. Purity and
concentration of the protein were determined with a Coomassie
Blue stained SDS-PAGE. Oligonucleotides containing the EVI1
binding site (5′-TCGACTTGACAAGATAAGCATAG-3′ and 3′-
AGCTGAACTGTTCTATTCGTATC-5′) were annealed and
end-labeled with [γ 32P]ATP to a specific activity of ∼4300
cpm/fmol. Binding reactions (50 μL, containing 10 000 cpm of
labeled oligonucleotides, 5 mM MgCl2, 0.01 mM ZnSO4, 50 mM
NaCl, 10 mM DTT, 50 mM HEPES, pH 7.9, 100 μg/mL BSA,
50 μg/mL, poly(dI-dC) (Sigma-Aldrich, St. Louis, MO), and 12.5%
glycerol) were incubated at 25 °C for 30 min prior to fractionation
on 4% nondenaturing PAGE (39:1 polyacrylamide−bisacrylamide,
0.5× TBE, and 2.5% glycerol). Active protein was determined by
DNA titration experiments as described.40 Polyamides were
preincubated at room temperature for 30 min with 32P-labeled
oligonucleotides in a 20 μL reaction containing 5 mM MgCl2,
0.01 mM ZnSO4, 50 mM NaCl, 10 mM DTT, 50 mM HEPES,
pH 7.9, 10 μg/mL BSA, 50 ug/mL, poly(dI-dC), and 12.5%
glycerol. The amount of oligonulceotides (labeled and unlabeled)
and protein varied in the femtomole range with each experiment,
as described under Results. 10 000 cpm were used for each
reaction, and the appropriate amount of unlabeled (cold) DNA
was added to give a total amount of 1250 fmol DNA per reaction.
Protein was added, and the binding reaction was performed as
described above. All dilutions were performed in binding buffer in
the presence of 100 μg/mL BSA. Dried gels were exposed to
BioMax MR film at −80 °C. Quantitation was performed with a
Molecular Dynamics Storm 840 phosphor imager using Quantity
One software. All reactions were performed in triplicate; results
were adjusted to normalize total counts in bound and free
oligonucleotides. The protein:DNA Ka was determined as
described,40 with the assumption that the stoichiometry of
protein/DNA binding is 1:1. From the plot of protein/DNA
complex [DP] against total concentration of protein [PT], the
slope can be determined and this can be used to determine Keq.
40
CAT Assay and Target Gene Quantitation. Cell line
6D-AP1713 was cultured in DMEM supplemented with 10%
calf serum, glutamine, penicillin, streptomycin, and 0.5 μg/mL
tetracycline, and plated on 10 cm plates at 2 × 105 per plate,
with three plates for each condition. The following day, cells
were washed and plated in medium devoid of tetracycline and
containing various concentrations of polyamide. After 48 h, the
cells were harvested and assayed for CAT activity and for
protein concentration as described.13
Inhibition Studies. Leukemic lines were plated in 96-well
plates at 3000 cells per well in 100 μL. 24 h later, polyamide
was added to various concentrations. At various times after
polyamide addition, 1 μC 3H-labeled thymidine was added, and
the cells were incubated for an additional 16 h. Cells were
harvested onto a glass filter paper sheet with a Tomtek cell
harvester; the sheet was saturated with scintillation fluid and
counted. For the colony formation assay, 10 000 cells were
plated in IL-3-supplemented mixed with 1.5 mL of methyl-
cellulose supplemented with 15% of WEHI condition media
and 1% glutamine and were plated on 30 mm plates (three
plates per sample). Cells were incubated in 37 °C for 1−2
weeks, and colonies were counted.
■ RESULTS
DNA Binding via First Set of Zinc Fingers Is Required
for Transformation. Toward the development of agents to
inhibit EVI1 action, we performed structure−function studies
to identify domains required for malignant transformation. We
previously described an R205N mutation, located at the +6
position of finger 6 in ZF1 that results in loss of sequence-
specific binding via ZF1 to the GACAAGATA motif.13 Here we
describe the development of EVI1 mutants that fail to bind
DNA via ZF2 (fingers 8−10). ZF2 binds with high affinity to
GAAGATGAG motif.3 On the basis of this understanding of
zinc finger structure41 (Figure 1A) and analysis of non-DNA
binding mutants in other systems,42,43 we predicted that finger
9, with N and R at positions +3 and +6 (Figure 1B), would
contribute considerable strength to binding and that R769 in
particular might be critical for domain 2 binding to DNA. To
test this, we mutated residue 769 to C, mimicking a mutation
found in NGFI-A that resulted in loss of DNA binding.43 We
fused EVI1 comprising zinc fingers 8, 9, and 10 (from N710 to
E821
38) both with and without the R769C mutation to
glutathione S-transferase (GST), purified by affinity chroma-
tography (Figure 1C), and tested for ability to bind to a double-
stranded radiolabeled oligonucleotide containing the GAA-
GATGAG motif (Figure 1D). This revealed that the R769C
mutant was essentially incapable of high affinity binding.
Next, we wanted to assess if DNA binding via ZF1 or ZF2 is
required for EVI1-mediated malignant transformation; for this
we employed mutants R205N and R769C, respectively. Rat1 cells
were transduced with pBabe-puro-based retroviruses bearing
HA-tagged EVI1, either wt, EVI1R205N, or EVI1R769C. Pools
transduced cells were shown to express EVI1 by Western blot,
with equal expression of the three constructs (Figure 1E). These
cells were seeded in soft agar, and colonies (>1 mm) were
enumerated after 10 days (Figure 1F). Rat1 cells transduced
with wildtype EVI1 yielded over 140 colonies/plate in soft agar;
the R769C mutant was nearly as transforming, yielding over 90
colonies. Remarkably, the R205N mutation was devoid of all
transforming ability, having essentially the same number of
colonies per plate as empty vector, pBabe-Puro (Figure 1F).
To further assess the effect of the R205N and R769C mutations,
we determined their effects on transformation of primary bone
marrow cells by the RUNX1-MDS1-EVI1 fusion protein
(termed RME), which is the product of the leukemia-associated
t(3;21) (Figure 1G). We employed a serial replating assay in
semisolid medium supplemented with growth factors.44 In two
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separate experiments, bone marrow was harvested 5 days after
treatment of C57BL/6 mice with 5-fluorouracil (5FU) and was
transduced with high titer MIGR1-based retrovirus containing
either wildtype EVI1p135, RME, RMER205N, RMER769C, or
RMED586A/L587S or no insert. As expected, vector-transduced
and untransduced bone marrow cells formed very few colonies
on the fourth plating (Figure 1H). RME proved to be
transforming, yielding significantly more colonies than the
vector-transduced or untransduced bone marrow cells (Figure 1H).
Strikingly, however, the R205N mutant was essentially devoid of
transforming ability (p < 0.001 relative to wildtype RME,
Student t test; Figure 1H). However, the R769C mutation in
ZF2 and the RMED586A/L587S mutant in the CtBP binding
domain were no different than wildtype RME protein, as was
EVI1p135 (Figure 1H). These findings are consistent with the
data obtained from the Rat1 transformation assay (Figure 1F).
Design of a Py-Im Polyamide To Block EVI1 Binding
via ZF1. The results of these two transformation assays clearly
indicated that the ability of EVI1 to transform cells is dependent
on its ability to bind to the GACAAGATA motif via ZF1. This
suggested that blocking the ability of the protein to bind to this
DNA sequence motif with a small molecule inhibitor such as a
polyamide would abrogate EVI1-induced transformation. We
thus designed a Py-Im polyamide to specifically interact with the
GACAA half of the motif and thereby block EVI1 binding to
DNA. We chose the GACAA half motif rather than the AGATA
portion due to the role of the latter in GATA protein function.
Based on the basis of the pairing rules, polyamide 1, which
consists of a sequence of the aromatic rings of N-methylpyrrole
(Py) and N -methylimidazole (Im) amino acids [ImPyPyPy-
(R)β‑H2N-γ-PyImPyPy-(+)-IPA (Figure 2)], should bind to the
sequence 5′-WGWCWW-3′, where W = A or T.15,45 As a
control, a “mismatch” polyamide 2 (ImPyPyPy-(R)β‑H2N-γ-
PyPyImPy-(+)-IPA; Figure 2) was synthesized, which targets
the sequence 5′-WGCWWW-3′. Versions of polyamide were
synthesized conjugated to isophthalic acid (IPA; Figure 2).
To assess whether polyamide 1 binds specifically to the GACA
motif, the magnitude of DNA thermal stabilization (ΔTm) of
DNA−polyamide complexes was determined by melting temper-
ature analysis (Table 1). A ΔTm reflects stronger stabilization of
the helix, indicating tighter binding of the polyamide to the duplex.
Relative to naked DNA (Tm = 50.2 °C), addition of match
polyamides 1 yielded the greatest increase in Tm (11.5−17.3 °C).
The value for IPA-conjugated polyamide (polyamide 1; ΔTm =
17.3) is similar to that obtained for polyamides targeting the
androgen receptor response element.30 The mismatch polyamides
had smaller ΔTm values, indicative of weaker binding (Table 1).
To assess the DNA binding specificity of polyamide 1 and
determine the affinity of polyamide−DNA complexes, DNase I
footprinting was performed using as a template a 5′-32P end-labeled
223 bp DNA fragment that contains a single GACAAGATA motif.5
Binding was performed in parallel with the mismatch polyamide 2.
This revealed the specificity of DNA binding for the polyamides and
the affinity of these interactions (Figure 3 and Table 2): polyamide
1 showed high affinity binding over the entire GACAAGATA EVI1
binding motif that was observed down to 300 pM, reflecting a Ka of
1.7 (±0.3) × 1010 M−1 (Table 2). Given that the polyamide was
designed to bind 5′-WGWCWW-3′, this extent of binding, over the
whole GACAAGATA motif, was expected. The binding affinity
obtained is in the same range as that obtained with other polyamides
designed to bind specific motifs (e.g., ref 24). Polyamide 2 binds to
the GATA motif but not GACAA, and only at the highest
concentrations of polyamide (Figure 3B, right, lanes 14 and 15),
corresponding to a Ka of binding 2 orders of magnitude lower than
the match polyamide (Ka = 1.0 (±0.3) × 10
8 M−1, Table 2).
Interestingly, there is a second binding site on the plasmid
(bracketed area II, TGTAA), with a binding affinity much lower
than that for the GACAAGATA motif (Table 2). The differential in
binding affinities between the desired interaction (between
polyamide 1 and site I, the GACAA motif) and the second site
(site II: TGTAA motif) is over 5-fold, possibly providing a
therapeutic window between specific and nonspecific effects.
Polyamide 1 Reduces EVI1 Binding Affinity. The
ability of polyamide 1 to inhibit EVI1 binding to its DNA
recognition site in vitro was assessed by electromobility shift
assay (EMSA). We determined the equilibrium constant (Keq)
for EVI1 binding to its cognate recognition site without
polyamide and with polyamide. In the first experiment, we used
only the match polyamide (polyamide 1) to see if it is capable
of inhibiting EVI1 binding at all. A protein titration was done at
a constant concentration of DNA, with and without polyamide
1 at a 4:1 ratio of polyamide to DNA (Figure 4A). For a total
DNA, 1250 fmol was used as previously described;13 polyamide
concentration was 5000 fmol in a 50 μL reaction. In the
absence of polyamide, the titration revealed a strong linear
relationship between input DNA and the amount shifted
Figure 2. Structure and binding of polyamide. Match (1) and mismatch (2) polyamides, with modifications as shown. Dark circles represent
imidazole (Im) and white circles pyrrole (Py). IPA indicates isophthalic acid.
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(Figure 4, panel B) with a Keq of 3.1 × 10
7 M−1 (Table 3).
Addition of polyamide 1 caused a significant drop in affinity of
DNA for protein, to 1.7% of control (Table 3). With polyamide
present, at the highest concentration of protein (700 fmol),
there is a slight shift, roughly equivalent to that obtained with
10 fmol of protein in the absence of polyamide; this represents
a remarkable inhibition of binding.
A second protein titration was done at a polyamide:DNA
ratio of 1:1. In this experiment, the mismatch polyamide
control was employed to assess the specificity of the inhibitory
effect exhibited by polyamide 1 (Figure 4C). Again, in the
absence of polyamide, protein titration results in a near linear
increase in DNA bound (Figure 4D). As in the first experiment,
pretreatment of the DNA with polyamide 1 yields a dramatic
inhibition of binding, giving a Keq 1.2% of that without
polyamide (Table 3). While the mismatch polyamide 2 did
cause a minor inhibition, likely due to nonspecific binding
(Table 3), it was not nearly as effective as the match polyamide,
indicating that polyamide 1 is more specific.
In these EMSA assays, we did not observe any retardation of
the radioactive probe by the polyamide, most likely due to the
relatively small molecular mass of polyamide 1.
Polyamide 1 Causes Inhibition of EVI1-Dependent
Transcriptional Activity. We next investigated the effect of
polyamide 1 on EVI1-dependent transcriptional regulation.
Since the transcriptional effects of native EVI1 isoforms on
transcription are not readily assayed, we initially employed a
synthetic reporter system we have designed and previously
described.13 This system involves the assaying transcriptional
activity of a chimeric EVI1-derived activator composed of ZF1
domain of EVI1 (zinc fingers 1−7) fused to the activation
domain of viral protein 16 (VP16) from herpes simplex virus 1
(HSV1). This protein has the binding specificity of ZF1
domain of EVI1 to the GACAAGATA motif but functions as a
potent transcriptional activator. Importantly, this activation
activity is completely dependent on the interaction between
EVI1 ZF1 and the GACAAGATA motif. We have shown
previously that this chimeric activator binds to and trans-
activates a chloramphenicol acetyl transferase (CAT) reporter
we have made bearing EVI1 binding sites within the promoter.
In addition, we have shown by chromatin immunoprecipitation
and gene expression analyses that this protein binds to the
promoter regions of endogenous genes that are candidate EVI1
targets.13 We have developed an NIH-3T3-derived cell line,
termed 6D, in which the EVI1-VP16 chimera is under the
control of a tetracycline operon;13 in the same cell line, there is
an autoregulatory tetracycline repressor-VP16 construct.46
Thus, in the presence of tetracycline, EVI1-VP16 is off but is
turned on within 6−10 h following removal of tetracycline. We
have further added to the 6D cell line a chromosome-
embedded CAT reporter harboring EVI1 binding sites within
the promoter region. This cell line, termed 6D+AP17, has
inducible CAT activity upon tetracycline removal that is
dependent on interaction between EVI1 zinc fingers and its
cognate binding site within the CAT promoter.
To test the ability of polyamide 1 to inhibit ZF1 binding to the
GACAAGATA motif in the CAT promoter, we removed
tetracycline from 6D+AP17 cells and simultaneously added
vehicle, polyamide 1, or the mismatched polyamide 2. We
incubated the cells for 48 h and then assayed CAT activity (Figure 5).
Doses of polyamide ranged from 0.1 to 1 μM. These doses of
polyamide 1 significantly suppressed EVI1-VP16-mediated
activation of the CAT reporter: activity was decreased 68 to
80% relative to minus Tet/no polyamide (all p values <0.01).
The suppression caused by the mismatched polyamide was not
as great20−58% reductionwith p values >0.01. However,
only at 1 μM concentration of polyamide was the match polyamide
significantly lower than the mismatch control (Figure 5).
Polyamide 1 Partially Inhibits Growth of DA-1 and
NFS-60 Cells. To assess the growth inhibitory effect of
polyamide 1 on myeloid cells, we tested the growth rate of two
different immortalized lines after incubation with match
polyamide. One of the two cell lines, NFS-60, has a high
level of EVI1 expression due to proviral insertional activation,
and the control cell line, FDCP, does not express EVI1.13 We
Figure 3. DNase I footprint of polyamide on DNA template. (A)
Schematic of the 223 bp double-stranded DNA template used for
DNase I footprint, derived by PCR from plasmid p406,5 with labeling
of the top strand as depicted. Below, DNA sequence showing the two
regions footprinted: EVI1 binding motif (sequence I) and the
TGTAAA motif (sequence II). (B) DNase I footprint with polyamides
1 (left) and 2 (right). Lanes 1, 2: Maxam−Gilbert sequencing
reactions for G and A, respectively; lane 3: no DNase I; lane 4: DNase
I, no polyamide; lanes 5−15: titration of polyamide from 10 pM to
1 μM. At bottom, graphic depiction of binding data to sequences I and
II, for polyamides 1 and 2. X-axis, polyamide concentration in moles;
Y-axis, fraction of maximal occupancy.
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incubated the two cell lines with 20 μM match polyamide 1 for
1 week and measured 3H-thymidine incorporation. The result
showed a 35.8% (Figure 6A, p = 0.0006) decrease of
incorporation in NFS-60, but no significant inhibition of
thymidine uptake was observed in FDCP. Next, we examined
whether the inhibition is dose-dependent; in this experiment
we also compared match (1) to mismatch (2) polyamide. We
treated NSF-60 cells for 1 week with polyamides 1 and 2 at
different doses, ranging from 0 to 20 μM, and tested the
growth. Our data demonstrated that with match polyamide 1
3H-thymidine incorporation was effectively decreased by 52.3%
(p = 0.000; Figure 6B), whereas it was slightly increased by
13.7% when treated with mismatch polyamide 2 (p = 0.0007).
Together, these data suggest that the EVI1-targeted polyamide
specifically inhibits EVI1-expressing cells in a dose-dependent
manner. However, polyamide treatment did not completely
inhibit leukemic cell growth.
Polyamide Significantly but Partially Inhibits RME-
Induced Transformation. In Figure 1H, we showed that
transformation by the RME leukemogenic fusion protein is
dependent on the ZF1 domain to transform primary bone
marrow cells in a serial replating assay. Given this dependence,
we predicted that polyamide 1 would be able to inhibit RME-
induced transformation of primary bone marrow cells, but not
marrow cells transformed by NUP98-HoxA9, an oncogene that
is independent of RME or EVI1. We thus transduced primary
bone marrow cells with either RME or NUP98-HoxA9 and
plated them in cytokine-supplemented methylcellulose that
contained either the match polyamide 1 or mismatch
polyamide 2. Colonies were then serially replated to three
platings. The results (Figure 6C) indicate a significant yet
incomplete inhibition of colony formation by RME with the
match polyamide 1, but not for NUP98-HoxA9-induced colony
formation. These data support the data described above that
the match polyamide 1 has a significant but partial ability to
inhibit EVI1 or RME-induced leukemic cell growth.
Figure 4. Electromobility shift assay (EMSA). (A) EVI1 protein titration from 0 to 700 fmol protein, as indicated, with 1250 fmol DNA template, in
the absence and presence of a 4-fold excess (relative to DNA; 5000 fmol) of match polyamide 1, as indicated. The probe is a double-stranded 20-mer
containing the GACAAGATA EVI1 binding motif. (B) Quantitation of EMSA data in panel A, displaying concentration DNA shifted relative to
protein concentration. The slope of the plot is used to calculate the Keq values in Table 3 as described in the Experimental Procedures. (C) EMSA
experiment using same probe as in panel A (1250 fmol); protein at various amounts as indicated are incubated with probe in the absence or presence
of match (polyamide 1) or mismatch (polyamide 2) polyamide at a 1:1 molar ratio relative to DNA probe. (D) Quantitation of EMSA data in panel
C, as in panel B.
Table 3. Decrease in Affinity of EVI1 for Cognate DNA Binding Site Due to Polyamide
experiment 1 experiment 2
polyamide slope Keq (M
−1) % of control slope Keq (M
−1) % of control
no polyamide (control) 0.66 3.1 × 107 100% 0.91 1.62 × 108 100%
polyamide 1 (match) 0.03 5.3 × 105 1.7% 0.108 1.94 × 106 1.19%
polyamide 2 (mismatch) nd nd nd 0.724 4.20 × 107 25.9%
Figure 5. Polyamide 1 inhibits EVI1-VP16-mediated activation of
EVI1 target. Y-axis shows normalized values of acetylated chlor-
amphenicol. Error bars denote standard error. Significance (p values)
is calculated with Student t test. Cells are washed of tetracycline to
induce EVI1-VP16, and polyamide, either match or mismatch, is added
at concentrations indicated. Cells are incubated 48 h and harvested for
CAT assay.
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■ DISCUSSION
The diagnosis of acute myeloid leukemia portends a particularly
poor prognosis. With current therapies, 5 year survival rates
range from 5 to 30%, depending on the subtype: leukemias
with t(8;21), inv(16), and t(15;17) have a significantly better
prognosis than those in the poor-risk category. This latter
category includes leukemias with abnormalities at 3q26, which
results in deregulated expression of EVI1. We have shown
previously that shRNA-mediated suppression of EVI1 results in
slowing of leukemic cell expansion in culture due to an increase
in apoptotic cell death via the intrinsic pathway.47 In the studies
described herein, we provide a first attempt at developing a
small molecule therapeutic specifically designed to block
transformation−critical EVI1 molecular interactions. Given
that EVI1 lacks enzymatic activity, the design of a small
molecule inhibitor is challenging. Since EVI1 is a nuclear
protein with sequence-specific DNA binding and transcrip-
tional regulatory activities, polyamides represent a logical
choice as potential therapeutic. In this paper, we demonstrate
that the ability of the EVI1 protein to transform cells is
dependent on its binding to DNA; this argues that blocking
DNA binding with a polyamide should block leukemic growth.
Polyamides hold significant promise in the treatment of
disease processes that are driven by aberrant transcriptional
regulation. Previous studies have reported efficacy of
polyamides in suppressing gene expression in vivo.24−27,48,49
Lai et al. reported the development of a polyamide directed
against Fat Specific Element 2 (FSE2) in the TGF-β promoter;
this polyamide significantly but not completely suppresses the
expression of TGF-β in cell culture.48 Yao et al. developed a
polyamide to target the AP-1 binding site in the lectin-like
oxidized low-density lipoprotein receptor 1 (LOX-1) and show
that it suppresses expression of the target in damaged vessels
and significantly ameliorates narrowing of arteries in damaged
vessels, a process that depends on LOX-1 expression. Their
data clearly show that polyamides can penetrate to the nucleus
of endothelial cells lining vessel walls following intravascular
injection of the polyamide into rats.49
Our polyamide design is based on binding rules previously
established by the Dervan lab for hairpin-configuration
polyamides such as the ones employed here: Im/Py binds to
G:A; Py/Py binds to A:T, and Py:Im binds to C:G. Thus, for
sequence GACA, we chose a polyamide with sequence
(ImPyPyPy-(R)β‑H2N-γ-PyImPyPy; polyamide 1); this folds
into a hairpin structure with resides paired as follows: Im/Py-
Py/Py-Py/Im-Py/Py. To test the specificity and affinity of
polyamide 1 for the GACA sequence, we first perform DNase I
footprinting that this polyamide binds to the GACAA motif at
Figure 6. Growth assessment of murine leukemic cells following treatment with polyamide. (A) Tritiated thymidine incorporation in myeloid cell
lines that do (NFS-60) or do not (FDCP) express EVI1, with or without 1 week incubation with 20 μM match polyamide, in triplicate. Bars denote
standard deviation. The decrease in thymidine uptake is significant for NFS-60 (p = 0.0006, Student t test), but not for FDCP cells. (B) NFS-60 cells
grown for 1 week with either match or mismatch polyamide at the doses indicated, followed by assessment of growth by 3H-thymidine
incorporation. Assays were performed in triplicate. Student t test revealed a significant decrease in incorporation at 20 μM of match relative to
untreated (p = 0.000). (C) Serial replating assay in cytokine-supplemented methylcellulose, of mouse bone marrow cells transduced with either RME
or NUP98-HoxA9, as shown, and treated with either match or mismatch polyamide (20 μM) as indicated. p value was calculated using Student t test.
Data are expressed as a percentage of the “control”, which is the number of colonies obtained with the specified oncogene at each round with
polyamide 2.
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very high affinity (association constant = 1.7 × 1010 M−1). The
specificity of binding is good, but not perfect: another site on
our DNase I protection probe (TGTAAA or TTTACA) also
bound, but at a 5-fold lower affinity. This binding can likely be
explained by the presence of an ACA motif within the
TTTACA sequence. Since the highest affinity is observed for
the GACAA motif, it may be possible to only bind the desired
sites through dose adjustment. Alternatively, it may be possible
to increase the specificity of binding by modifying the structure
of polyamide 1, perhaps incorporating derivatives of the
standard imidazole/pyrrole moieties. For instance, Py/Hp has
been shown to bind more specifically to A:T pairs than the Py/
Py used in polyamide 1.15 However, hydroxypyrrole is unstable
and can degrade over time; more stable alternative structures
has been discussed.15
Given the high affinity of polyamide 1 for the GACAA motif,
it is not surprising that it effectively blocks the ability of EVI1
bind to this site in vitro, as demonstrated by EMSA assay
(Figure 4). We were also able to demonstrate inhibition of
EVI1 binding in vivo, using our 6D+AP17 cell line (Figure 5).
Importantly, the CAT reporter we are using is embedded in the
chromosome, so it is chromatinized, unlike transient trans-
fection constructs used by other investigators.48
Finally, we assess the ability of polyamide 1 to inhibit
leukemic cell growth. While no effect on growth is seen in cell
lines that lack EVI1 expression, a small but significant effect is
seen on leukemic cells that have provirally activated EVI1 allele.
These results raise the hopeful possibility that with further
optimization of administration strategies or in drug design, a
highly specific and effective novel anti-EVI1 therapy can be
developed. One issue to be addressed is the efficacy of cellular
uptake: while a fluorescently tagged polyamide was taken into
cells and localized to the nucleus (data not shown), its
intranuclear concentration may have been low, since the
intensity of fluorescent staining was lower that that seen in
polyamide-treated permeabilized cells, into which the drug
freely enters (data not shown). Leukemic cells are known to
possess effective P1 glycoprotein-type multidrug resistance
export pumps;50 we assessed the importance of these to the low
entry of polyamide into cells by coadministering verapimil, an
effective inhibitor of these pumps, and no marked improvement
of uptake was observed (data not shown). Other options exist
for increasing cellular uptake. These include manipulating the
charge on the γ-turn of the hairpin: Previous studies by the
Dervan laboratory have noted that α-NHAc substituted γ-turns
often facilitate better cellular uptake compared to unsubstituted
(lacking the NHAc moiety) γ-turns.23 In this study we are
employing β-substituted turns, which is a recent advance in
polyamide technology.29 Nonetheless, changing the −NH3+
moiety (see Figure 2) to an −NHAc moiety may increase
cellular uptake. This is the focus of current experimentation.
Specific Role of ZF1 and Relevant Target Genes for
Malignant Transformation. To eliminate DNA binding via
ZF1 and ZF2, we created point mutations rather than large
deletions, thus minimizing the possibility that other functions
of the zinc fingers, such as protein:protein interactions (e.g.,
with SMAD proteins51,52) are disrupted. Previous studies have
suggested that DNA binding via ZF1 is required for EVI1-
mediated malignant transformation.4 However, the deletions
used also abrogated binding to SMAD proteins,51 making a
definitive conclusion difficult. To address this, and to assess the
role of DNA binding via ZF2 in transformation, we tested the
ability of two different DNA binding-deficient mutants, one in
ZF1 (EVI1R205N
13) and one in ZF2 (EVI1R769C), for their ability
to transform cells using the Rat1 transformation assay for
EVI1.7 The results of these experiments clearly indicate that
EVI1-induced malignant transformation is dependent on DNA
binding via ZF1; however, they do not indicate what are the
relevant and critical DNA targets. Recent chromatin
immunoprecipitation-sequencing (ChIP-Seq) experiments we
have performed have shed new light on the issue of leukemia-
relevant EVI1 target genes and suggest that one reason for the
limited efficacy of polyamide 1 in inhibiting the growth of
EVI1-expressing leukemias is that we have not targeted the
correct sequence. Thus, further advances in targeting EVI1 with
polyamides will likely require more information concerning the
identity of key transcriptional targets for EVI1 and the exact
nature of the DNA motif by which EVI1 regulates these genes.
The identification of critical target genes that are essential for
leukemogenesis has been difficult. The GACAAGATA motif to
which ZF1 binds was first identified by an iterative site-
selection strategy,1 selecting for the highest affinity binding
under EMSA conditions; selection of EVI1 binding sites in
mouse genomic DNA using an in vitro filter binding assay
yielded the same motif.53 These strategies for binding site
identification are flawed in that they select for the highest
affinity binders using purified EVI1 protein under artificial
conditions; native conditions within the nucleus differ markedly
due to the presence of other proteins and chromatinized DNA
packed within higher order structures. In addition, it is possible
that bona f ide DNA binding sites for EVI1 do not have the
highest affinity, since too low an off-rate might not allow for
fine regulation of gene expression.
To further refine our understanding of true EVI1 target
genes, we have recently performed ChIP-Seq experiments using
mouse leukemic cell lines that overexpress EVI1.47 This
approach identified nearly 5000 different EVI1 binding sites
within the genome, and some of these sites suggest compelling
mechanisms for leukemogenesis. Interestingly, only a small
minority of these contained the DNA motifs identified by site
selection,1,3 and none was the same as the genomic fragments
we selected using an in vitro filter binding approach.53 Even the
sites identified by our in vivo selection strategy13 were only
rarely occupied in vivo within leukemic cells. We are in the
process of confirming the location of EVI1 binding that we
obtained from ChIP-Seq experiments.
The discrepancy between our previous selection schemes and
the data from ChIP-Seq experiments indicates that bona f ide
EVI1 binding sites and bona f ide EVI1 target gene still need to
be more thoroughly delineated and characterized. The
identification of these leukemia-critical targets, and the site to
which EVI1 binds within these genes, remains a critical goal.
Once these are identified, it will likely be possible to block these
interactions with polyamides and thereby inhibit the growth of
EVI1-driven myeloid leukemias. The data presented here
clearly indicate that EVI1 binding to DNA can be effectively
blocked both in vivo and in vitro with polyamides. With further
improvements in nuclear localization of polyamides and
knowledge of leukemia-critical targets, we contend that these
agents can become very effective therapeutics for the treatment
of myeloid leukemia.
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Figure S1: intermediate compounds in polyamide synthesis.
Shown is the base polyamide structure from which the IPA and
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FITC derivatives were synthesized; compounds 5 and 6
correspond to the base polyamide with the side chain
modifications indicated. This material is available free of charge
via the Internet at http://pubs.acs.org.
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